sellModerate
Versant Venture Capital VI, L.P. sold $2.5M of LVTX
owner at LAVA Therapeutics NV. 1,684,434 shares at an average of $1.49, traded Sep 16, 2025, filed Sep 18, 2025.
Warning score
47Value
$2.5M
1,684,434 shares
Holdings after
532,870
-49% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$2.5M at market
- +10Share of holdings soldSold 49% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-207677, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2025 | SOpen-market sale Common Stock | -307,707 | $1.53 | $472k | 3,099,450 | Sep 18, 2025 |
| Sep 16, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -192,293 | $1.53 | $295k | 988,387 | Sep 18, 2025 |
| Sep 17, 2025 | SOpen-market sale Common Stock | -362,806 | $1.49 | $540k | 2,736,644 | Sep 18, 2025 |
| Sep 17, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -226,726 | $1.49 | $338k | 761,661 | Sep 18, 2025 |
| Sep 18, 2025 | SOpen-market sale Common Stock | -366,111 | $1.44 | $528k | 2,370,533 | Sep 18, 2025 |
| Sep 18, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -228,791 | $1.44 | $330k | 532,870 | Sep 18, 2025 |
Related signals
Other insiders at LAVA Therapeutics NV and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | LVTXsell LAVA Therapeutics NV | Gilde Healthcare U.A. Cooperatieve IV owner | $4.2M 2,871,370 shares | -97% | |
| 33Weak | LVTXsell LAVA Therapeutics NV | Gilde Healthcare U.A. Cooperatieve IV owner | $719k 475,027 shares | -9% | |
| 24Weak | LVTXsell LAVA Therapeutics NV | Gilde Healthcare U.A. Cooperatieve IV owner | $198k 126,992 shares | -2% | |
| 57Moderate | LVTXsell LAVA Therapeutics NV | Versant Venture Capital VI, L.P. owner | $4.1M 2,903,403 shares | -122% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.